Navigation Links
Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor
Date:5/13/2009

NERVIANO, Italy, May 13 /PRNewswire/ -- The FDA has approved an Investigational New Drug (IND) application by Nerviano Medical Sciences to begin a phase I clinical study with its selective PLK-1 small molecule inhibitor for the treatment of cancer. PLK-1 is a mitotic kinase required for the proliferation of cancer cells. This new compound is orally bioavailable, highly efficient and well tolerated in preclinical models of cancer after repeated dosing. This unique inhibitor adds another promising candidate to the pipeline of innovative cell cycle targets with different mechanisms of action in clinical development which have been discovered and developed by NMS. These include inhibitors of CDK, Aurora and CDC-7. An IND for an inhibitor of CDC-7 was approved by the FDA in January this year and the first patients were treated with the compound in April. NMS CDK and Aurora inhibitors are in phase I and II clinical development, respectively, and are starting to show promising activity in specific patient populations.

The clinical development path foresees application of the NMS PLK-1 inhibitor in solid and hematological indications. "I am pleased to see the second IND approval this year and I highly appreciate the consistant delivery of high quality clinical candidates by the Nerviano site" comments Dr. Francesco Colotta, VP R&D at NMS.

Nerviano Medical Sciences (NMS)

Nerviano Medical Sciences is the largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe. Research activities in Nerviano generate on average two clinical candidate molecules per year. NMS takes advantage of strategic alliances with biotechnology as well as pharmaceutical companies to secure its long term business sustainability. The Company has already finalized partnerships with major companies such as Pfizer Inc., Bristol-Myers Squibb C
'/>"/>

SOURCE Nerviano Medical Sciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical Announces First quarter 2009 results
2. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
3. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
4. Medical Simulation Corporation to Introduce Central Line Management Program at the National Teaching Institute and Critical Care Exposition
5. ATS Medical Announces Participation in the Annual Meeting of the American Association for Thoracic Surgeons
6. University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System
7. Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury
8. Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff
9. Nfocus Neuromedical Appoints Robert OHolla to Head Regulatory
10. Resonant Medical Expands Sales Organization with Appointment of Vice President of Global Sales and Marketing
11. BioMS Medical to present at Alberta Economic Forum in Geneva
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud ... partially hydrolyzed gluten in foods, has been accepted by AOAC International as Official ... Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific ...
(Date:7/30/2015)... CAMBRIDGE, Mass. , July 30, 2015 /PRNewswire/ ... software solutions for the interpretation and analysis of ... Matthew Fischer has joined the company ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... astounding capabilities to integrate, interpret, analyze and explore ...
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)... 2015   Senomyx , Inc. (NASDAQ: SNMX ... to discover, develop, and commercialize novel flavor ingredients for ... financial results for the second quarter 2015. ... remain on track to achieve our commercial and financial ... of the Company. "Since our last quarterly earnings report, ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... assay effectively identifies melanoma, LA JOLLA, Calif., ... diagnostics for the early detection of,melanoma and other ... Cancer Research on its non-invasive assay that distinguishes ... Genomic Assay for,the Detection of Melanoma in Suspicious ...
... CEDAR KNOLLS, N.J., April 15 Emisphere,Technologies, Inc. ... will host its,Annual Stockholders Meeting on Thursday, May ... Two Whippany Road, Morristown, New Jersey. The,meeting will ... TECHNOLOGIES, INC., Emisphere Technologies, Inc. is a ...
... -ARIUS report new data and program updates on cancer stem cell ... ... April 15 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), a biotechnology company ... it will be presenting new,findings and program updates related to its ...
Cached Biology Technology:DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR 2Emisphere Technologies To Hold Annual Stockholders Meeting on May 8, 2008 2ARIUS presents new findings for anti-cancer antibody programs at AACR 2ARIUS presents new findings for anti-cancer antibody programs at AACR 3ARIUS presents new findings for anti-cancer antibody programs at AACR 4ARIUS presents new findings for anti-cancer antibody programs at AACR 5
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
(Date:7/20/2015)... -- Acuity Market Intelligence,s latest research "The Global Biometrics ... Privacy" forecasts that between 2014 and 2020 nearly ... to smart mobile devices by 2.2 billion mobile ... to generate more than $67.9 billion in total ...    "Biometrics is at the center ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... Baltimore, MD The human genome shares several peculiarities with the ... Our genetic blueprint contains numerous entities known as transposons, or ... to place on the chromosomes within a cell. ... transposon elements and the decaying remains of former transposons that ...
... meeting of the American Fisheries Society will take place in ... conference is "New Frontiers in Fisheries Management and Ecology: Leading ... http://afs2011.org/ All talks will be at the ... Eat but don,t get eaten: after restoration, young salmon better ...
... discovery by the University of Colorado Boulder and the ... "power plants" within cells known as mitochondria has implications ... and conditions due to mitochondrial defects. Led by ... collaboration with the UC-Davis team led by Professor Jodi ...
Cached Biology News:A 'jumping gene's' preferred targets may influence genome evolution 2A 'jumping gene's' preferred targets may influence genome evolution 3USGS research frontiers on fish at the American Fisheries Society Conference 2USGS research frontiers on fish at the American Fisheries Society Conference 3USGS research frontiers on fish at the American Fisheries Society Conference 4USGS research frontiers on fish at the American Fisheries Society Conference 5USGS research frontiers on fish at the American Fisheries Society Conference 6USGS research frontiers on fish at the American Fisheries Society Conference 7New cellular surprise may help scientists better understand human mitochondrial diseases 2
Request Info...
... CultureWell cell culture systems provide ... cultured cells for staining and ... silicone gaskets preassembled with standard ... plates. The entire system is ...
... The Captivate magnetic separator ... be used in conjunction with ... C-21474, C-21476) or other magnetic ... most 96-well microplates. Cell Biology ...
ANTI L-DOPA...
Biology Products: